New treatment for patients with rare liver cancer
Intra-arterial lutetium-177-dotatate for treatment of patients with neuroendocrine tumor liver metastases: the LUITA study
At time of diagnosis, 45% of patients with neuro-endocrine tumors (NETs) present with metastasis. The overall 5-year survival rate of patients with NETs is approximately 60%. New advancements have been made in the treatment of NETs. IV administered somatostatin-bound radionuclides (i.e. 177Lu-dotatate) have been shown to improve tumor response rates and survival. Despite of the increased tumor response rate and survival, liver metastasis still remain the major cause of morbidity and mortality in these patients.
The so-called European Neuro-Endocrine Tumor Society Centers of Excellence of the Erasmus MC, UMC Utrecht and AVL-NKI join forces, in collaboration with the producer of 177Lu-dotatate, to improve treatment for patients with liver metastases. They propose a phase I multi-center study in which patients with NETs with liver metastasis are treated via a catheter in the hepatic artery that feeds the tumors. With this method they aim to improve the radiation absorbed dose in the treated tumors. An increased tumor absorbed dose may lead to better outcome.
At the end of this study it can be said whether administration of the drug 177Lu-dotatate straight in the tumor feeding artery leads to improved targeting and response.